Proleukin Market Report 2026

Proleukin Market Overview

• The Proleukin market growth in the historic period has been driven by approval for cystic fibrosis management, proven mucus thinning efficacy • Market expansion is supported by rising cf diagnosis rates, improved life expectancy of patients • Growth Driver: Rising Cancer Incidence Fuels Growth In The Proleukin Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Proleukin Market?

Proleukin is the brand name for aldesleukin, a recombinant form of interleukin-2 (IL-2), a naturally occurring protein in the body. Proleukin is classified as a biologic therapy and is primarily used in oncology and immunotherapy. It works by stimulating the growth and activity of certain white blood cells (lymphocytes), enhancing the immune system's ability to recognize and attack cancer cells. The main types of proleukin are injection, powder, and others. Proleukin injection is a liquid formulation of aldesleukin, a recombinant interleukin-2 used for immune system modulation. It is used for various clinical indications such as metastatic renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), other indications, and various therapeutic areas such as oncology, immunology, and others. These are distributed through both online and offline channels. It is applied in hospitals and pharmacies for both adults and pediatrics.

What Is The Proleukin Market Growth Forecast?

The proleukin market size is expected to see strong growth in the next few years. It will grow to $1.68 million in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rising cf diagnosis rates, improved life expectancy of patients, expansion of homecare therapy use, growth of specialty pharmacies, continued respiratory innovation. Major trends in the forecast period include standard of care in cystic fibrosis treatment, long term use in mucus clearance therapy, home based nebulized treatment adoption, hospital and homecare integration, continued reliance on enzyme therapies.

Global Proleukin Market Segmentation

1) By Type: Injection, Powder, Other Types 2) By Therapeutic Area: Oncology, Immunology, Other Therapeutic Areas 3) By Clinical Indication: Metastatic Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC), Other Indications 4) By Application: Hospital, Pharmacy 5) By End-User: Adults, Pediatrics

What Are The Drivers Of The Proleukin Market?

The growing cancer disease is expected to drive the growth of the proleukin market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which can invade nearby tissues and, if untreated, may metastasize to other parts of the body. The increasing prevalence of cancer can be attributed to factors such as an aging population, better detection methods, lifestyle changes, environmental exposures, and improved survival rates, all of which contribute to more people being diagnosed and living with cancer. Proleukin, a high-dose interleukin-2 therapy, helps cancer patients by stimulating the immune system's natural ability to target and destroy cancer cells, offering a potential treatment option for advanced malignancies such as metastatic melanoma and renal cell carcinoma. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, an estimated 20 million new cancer cases and 9.7 million deaths were reported in 2022, with projections suggesting a 77% increase to over 35 million new cases by 2050. Therefore, the growing cancer disease is driving the growth of the proleukin industry. The increasing research and development activities are expected to drive the growth of the proleukin market going forward. Research and development (R&D) activities involve the systematic investigation and innovation aimed at creating new products, improving existing ones, or developing new technologies and solutions through scientific and technical research. Research and development activities are rising due to the growing demand for innovation, technological advancements, and the need to address emerging global challenges in various industries. Research and development activities positively impact Proleukin by enhancing its efficacy, exploring new cancer indications, improving delivery mechanisms, and potentially reducing side effects, thereby broadening its clinical utility and patient reach. For instance, in February 2025, according to the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, U.S. research and development expenditures rose from $892 billion in 2022 to $940 billion in 2023, reflecting an increase of $48 billion. Therefore, the increasing research and development activities are driving the growth of the proleukin industry.

Key Players In The Global Proleukin Market

Major companies operating in the proleukin market are Novartis Pharmaceuticals Corporation

What Are Latest Mergers And Acquisitions In The Proleukin Market?

In May 2023, Iovance Biotherapeutics, a US-based biotechnology company that develops innovative T-cell-based cancer immunotherapies, acquired Proleukin (aldesleukin) from Clinigen Limited for an undisclosed amount. This acquisition enables Iovance Biotherapeutics to enhance its T-cell-based cancer immunotherapy platform by integrating Proleukin (aldesleukin), a key immunotherapy agent, to improve the effectiveness of its tumor-infiltrating lymphocyte (TIL) therapies, thus advancing its pipeline of innovative cancer treatments and strengthening its position in the competitive oncology market. Clinigen Group is a UK-based company that offers Proleukin (aldesleukin).

Regional Insights

North America was the largest region in the proleukin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Proleukin Market?

The proleukin market consists of sales of cancer vaccines, biosimilars, immune checkpoint inhibitors and adjuvants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Proleukin Market Report 2026?

The proleukin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the proleukin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.